Be one of the few Get it before everybody else: Fortress Biotech, Inc. (NASDAQ: FBIO)

On 28 May 2020, Fortress Biotech, Inc. (NASDAQ: FBIO) spotted trading -3.46% off 52-week high price. On the other end, the stock has been noted 188.68% away from the low price over the last 52-weeks. The stock changed 0.08% to recent value of $3. The stock transacted 143877 shares during most recent day however it has an average volume of 561.58K shares.

Fortress Biotech, Inc. (FBIO) recently reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2019.

Financial Results:

As of December 31, 2019, Fortress’ consolidated cash, cash equivalents, short-term investments (certificates of deposit) and restricted cash totaled $153.4M, contrast to $156.0M as of September 30, 2019, and $99.2M as of December 31, 2018, a decrease of $2.6M for the fourth quarter and a raise of $54.2M for the full year.

Fortress’ net revenue totaled $36.6M as of December 31, 2019, which includes $34.9M in net revenue generated from our marketed dermatology products, which represented growth of 49% year-over-year. This compares to a total of $26.9M in net revenue as of December 31, 2018.

Consolidated research and development expenses were $75.2M for the year ended December 31, 2019, of which $72.6M was related to partner companies. This compares to $83.3M for 2018, of which $76.8M was related to partner companies. Non-cash, stock-based compensation expenses included in research and development were $2.8M for the year ended December 31, 2019, contrast to $5.3M for 2018.

Research and development expenses from license acquisitions totaled $6.1M for the year ended December 31, 2019, contrast to $4.1M for 2018.

Consolidated general and administrative expenses were $55.6M for the year ended December 31, 2019, of which $37.3M was related to partner companies. This compares to $53.4M for 2018, of which $33.0M was related to partner companies. Non-cash, stock-based compensation expenses included in general and administrative expenses were $10.4M for the year ended December 31, 2019, contrast to $9.7M for 2018.

Consolidated net loss attributable to ordinary stockholders was $40.0M, or $0.73 per share, for the year ended December 31, 2019, contrast to a net loss attributable to ordinary stockholders of $84.1M, or $1.94 per share, for 2018.

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions.

Its earnings per share (EPS) expected to touch remained 56.50% for this year while earning per share for the next 5-years is expected to reach at 43.40%. FBIO has a gross margin of 71.90%. According to the most recent quarter its current ratio was 3.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 23.15% from the mean of 20 days, 44.59% from mean of 50 days SMA and performed 52.63% from mean of 200 days price. Company’s performance for the week was 17.65%, 47.06% for month and YTD performance remained 16.73%.

Leave a Reply

Your email address will not be published. Required fields are marked *